Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Dec;32(12):1839–1844. doi: 10.1128/aac.32.12.1839

(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication.

R Snoeck 1, T Sakuma 1, E De Clercq 1, I Rosenberg 1, A Holy 1
PMCID: PMC176029  PMID: 2854454

Abstract

From a series of phosphonylmethoxyalkylpurine and -pyrimidine derivatives, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] emerged as a particularly potent and selective inhibitor of the replication of human cytomegalovirus (CMV). Its potency against CMV was similar to that of the structurally related adenine derivative (S)-HPMPA but higher than that of the reference compounds phosphonoformate and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). The minimum concentrations of phosphonoformate, DHPG, (S)-HPMPA, and (S)-HPMPC required to inhibit CMV plaque formation by 50% were 15, 0.7, 0.1, and 0.07 microgram/ml, respectively. The selectivity indices of phosphonoformate, DHPG, (S)-HPMPA, and (S)-HPMPC, as determined by the ratio of the 50% inhibitory concentration for cell growth to the 50% inhibitory concentration for plaque formation for CMV (AD-169 strain), were 14, 150, 200 and 1,500, respectively. Corresponding values for the CMV Davis strain were 20, 200, 100, and 1,000, respectively. (S)-HPMPC was inhibitory to CMV plaque formation even when added to the cells at 24 or 48 h postinfection. When (S)-HPMPC was added immediately postinfection, a 24- or 48-h incubation time sufficed to obtain a marked inhibitory effect on CMV replication. Such limited incubation time was insufficient for DHPG to achieve any protection against CMV.

Full text

PDF
1839

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chachoua A., Dieterich D., Krasinski K., Greene J., Laubenstein L., Wernz J., Buhles W., Koretz S. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine (ganciclovir) in the treatment of cytomegalovirus gastrointestinal disease with the acquired immunodeficiency syndrome. Ann Intern Med. 1987 Aug;107(2):133–137. doi: 10.7326/0003-4819-107-2-133. [DOI] [PubMed] [Google Scholar]
  2. Colacino J. M., Lopez C. Antiviral activity of 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl-5-iodocytosine against human cytomegalovirus in human skin fibroblasts. Antimicrob Agents Chemother. 1985 Aug;28(2):252–258. doi: 10.1128/aac.28.2.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. De Clercq E. Biochemical aspects of the selective antiherpes activity of nucleoside analogues. Biochem Pharmacol. 1984 Jul 15;33(14):2159–2169. doi: 10.1016/0006-2952(84)90649-x. [DOI] [PubMed] [Google Scholar]
  4. De Clercq E., Holý A., Rosenberg I., Sakuma T., Balzarini J., Maudgal P. C. A novel selective broad-spectrum anti-DNA virus agent. Nature. 1986 Oct 2;323(6087):464–467. doi: 10.1038/323464a0. [DOI] [PubMed] [Google Scholar]
  5. Field A. K., Davies M. E., DeWitt C., Perry H. C., Liou R., Germershausen J., Karkas J. D., Ashton W. T., Johnston D. B., Tolman R. L. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4139–4143. doi: 10.1073/pnas.80.13.4139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Keay S., Bissett J., Merigan T. C. Ganciclovir treatment of cytomegalovirus infections in iatrogenically immunocompromised patients. J Infect Dis. 1987 Dec;156(6):1016–1021. doi: 10.1093/infdis/156.6.1016. [DOI] [PubMed] [Google Scholar]
  7. Laskin O. L., Cederberg D. M., Mills J., Eron L. J., Mildvan D., Spector S. A. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med. 1987 Aug;83(2):201–207. doi: 10.1016/0002-9343(87)90685-1. [DOI] [PubMed] [Google Scholar]
  8. Laskin O. L., Stahl-Bayliss C. M., Kalman C. M., Rosecan L. R. Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS. J Infect Dis. 1987 Feb;155(2):323–327. doi: 10.1093/infdis/155.2.323. [DOI] [PubMed] [Google Scholar]
  9. Lin J. C., DeClercq E., Pagano J. S. Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob Agents Chemother. 1987 Sep;31(9):1431–1433. doi: 10.1128/aac.31.9.1431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Macher A. M., Reichert C. M., Straus S. E., Longo D. L., Parrillo J., Lane H. C., Fauci A. S., Rook A. H., Manischewitz J. F., Quinnan G. V., Jr Death in the AIDS patient: role of cytomegalovirus. N Engl J Med. 1983 Dec 8;309(23):1454–1454. doi: 10.1056/NEJM198312083092312. [DOI] [PubMed] [Google Scholar]
  11. Mar E. C., Cheng Y. C., Huang E. S. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1983 Oct;24(4):518–521. doi: 10.1128/aac.24.4.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mar E. C., Patel P. C., Cheng Y. C., Fox J. J., Watanabe K. A., Huang E. S. Effects of certain nucleoside analogues on human cytomegalovirus replication in vitro. J Gen Virol. 1984 Jan;65(Pt 1):47–53. doi: 10.1099/0022-1317-65-1-47. [DOI] [PubMed] [Google Scholar]
  13. Quinnan G. V., Jr, Masur H., Rook A. H., Armstrong G., Frederick W. R., Epstein J., Manischewitz J. F., Macher A. M., Jackson L., Ames J. Herpesvirus infections in the acquired immune deficiency syndrome. JAMA. 1984 Jul 6;252(1):72–77. [PubMed] [Google Scholar]
  14. Smee D. F., Martin J. C., Verheyden J. P., Matthews T. R. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother. 1983 May;23(5):676–682. doi: 10.1128/aac.23.5.676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Suzuki S., Saneyoshi M., Nakayama C., Nishiyama Y., Yoshida S. Mechanism of selective inhibition of human cytomegalovirus replication by 1-beta-D-arabinofuranosyl-5-fluorouracil. Antimicrob Agents Chemother. 1985 Aug;28(2):326–330. doi: 10.1128/aac.28.2.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Tocci M. J., Livelli T. J., Perry H. C., Crumpacker C. S., Field A. K. Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replication. Antimicrob Agents Chemother. 1984 Feb;25(2):247–252. doi: 10.1128/aac.25.2.247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Tolman R. L., Field A. K., Karkas J. D., Wagner A. F., Germershausen J., Crumpacker C., Scolnick E. M. 2'-Nor-cGMP: a seco-cyclic nucleotide with powerful anti-DNA-viral activity. Biochem Biophys Res Commun. 1985 May 16;128(3):1329–1335. doi: 10.1016/0006-291x(85)91086-1. [DOI] [PubMed] [Google Scholar]
  18. Turk S. R., Shipman C., Jr, Nassiri R., Genzlinger G., Krawczyk S. H., Townsend L. B., Drach J. C. Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus. Antimicrob Agents Chemother. 1987 Apr;31(4):544–550. doi: 10.1128/aac.31.4.544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Votruba I., Bernaerts R., Sakuma T., De Clercq E., Merta A., Rosenberg I., Holý A. Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis. Mol Pharmacol. 1987 Oct;32(4):524–529. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES